Metixene

Profil Farmakokinetik

Waktu Paruh (Half-Life) -

Volume Distribusi -

Klirens (Clearance) -

Absorpsi

Absorbed in the gastrointestinal tract following oral administration, however the extent of absorption is not known.

Metabolisme

Hepatic. Metabolism occurs via sulfoxydation and N-demethylation.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

552 Data

Aclidinium	The risk or severity of adverse effects can be increased when Metixene is combined with Aclidinium.
Mianserin	Mianserin may increase the anticholinergic activities of Metixene.
Mirabegron	The risk or severity of urinary retention can be increased when Metixene is combined with Mirabegron.
Potassium chloride	The risk or severity of gastrointestinal ulceration can be increased when Metixene is combined with Potassium chloride.
Pramlintide	The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Metixene.
Secretin porcine	The therapeutic efficacy of Secretin porcine can be decreased when used in combination with Metixene.
Tiotropium	The risk or severity of adverse effects can be increased when Metixene is combined with Tiotropium.
Topiramate	The risk or severity of hyperthermia and oligohydrosis can be increased when Metixene is combined with Topiramate.
Umeclidinium	The risk or severity of adverse effects can be increased when Metixene is combined with Umeclidinium.
Methylphenidate	The risk or severity of adverse effects can be increased when Methylphenidate is combined with Metixene.
Dexmethylphenidate	The risk or severity of adverse effects can be increased when Dexmethylphenidate is combined with Metixene.
Metoclopramide	The therapeutic efficacy of Metixene can be decreased when used in combination with Metoclopramide.
Glycopyrronium	The risk or severity of adverse effects can be increased when Metixene is combined with Glycopyrronium.
Botulinum toxin type A	The risk or severity of adverse effects can be increased when Metixene is combined with Botulinum toxin type A.
Glucagon	Metixene may increase the gastrointestinal motility reducing activities of Glucagon.
Sulpiride	Metixene may increase the anticholinergic activities of Sulpiride.
Botulinum toxin type B	The risk or severity of adverse effects can be increased when Metixene is combined with Botulinum toxin type B.
Eluxadoline	The risk or severity of constipation can be increased when Metixene is combined with Eluxadoline.
Ramosetron	The risk or severity of constipation can be increased when Metixene is combined with Ramosetron.
Naltrexone	The risk or severity of adverse effects can be increased when Metixene is combined with Naltrexone.
Bezitramide	The risk or severity of adverse effects can be increased when Metixene is combined with Bezitramide.
Tramadol	The risk or severity of adverse effects can be increased when Metixene is combined with Tramadol.
Morphine	The risk or severity of adverse effects can be increased when Metixene is combined with Morphine.
Codeine	The risk or severity of adverse effects can be increased when Metixene is combined with Codeine.
Hydromorphone	The risk or severity of adverse effects can be increased when Metixene is combined with Hydromorphone.
Methadone	The risk or severity of adverse effects can be increased when Metixene is combined with Methadone.
Meperidine	The risk or severity of adverse effects can be increased when Metixene is combined with Meperidine.
Oxycodone	The risk or severity of adverse effects can be increased when Metixene is combined with Oxycodone.
Butorphanol	The risk or severity of adverse effects can be increased when Metixene is combined with Butorphanol.
Dextropropoxyphene	The risk or severity of adverse effects can be increased when Metixene is combined with Dextropropoxyphene.
Pentazocine	The risk or severity of adverse effects can be increased when Metixene is combined with Pentazocine.
Sufentanil	The risk or severity of adverse effects can be increased when Metixene is combined with Sufentanil.
Alfentanil	The risk or severity of adverse effects can be increased when Metixene is combined with Alfentanil.
Fentanyl	The risk or severity of adverse effects can be increased when Metixene is combined with Fentanyl.
Nalbuphine	The risk or severity of adverse effects can be increased when Metixene is combined with Nalbuphine.
Levorphanol	The risk or severity of adverse effects can be increased when Metixene is combined with Levorphanol.
Remifentanil	The risk or severity of adverse effects can be increased when Metixene is combined with Remifentanil.
Buprenorphine	The risk or severity of adverse effects can be increased when Metixene is combined with Buprenorphine.
Hydrocodone	The risk or severity of adverse effects can be increased when Metixene is combined with Hydrocodone.
Diphenoxylate	The risk or severity of adverse effects can be increased when Metixene is combined with Diphenoxylate.
Oxymorphone	The risk or severity of adverse effects can be increased when Metixene is combined with Oxymorphone.
Dezocine	The risk or severity of adverse effects can be increased when Metixene is combined with Dezocine.
Levacetylmethadol	The risk or severity of adverse effects can be increased when Metixene is combined with Levacetylmethadol.
Methadyl acetate	The risk or severity of adverse effects can be increased when Metixene is combined with Methadyl acetate.
Dihydroetorphine	The risk or severity of adverse effects can be increased when Metixene is combined with Dihydroetorphine.
Diamorphine	The risk or severity of adverse effects can be increased when Metixene is combined with Diamorphine.
Ethylmorphine	The risk or severity of adverse effects can be increased when Metixene is combined with Ethylmorphine.
Etorphine	The risk or severity of adverse effects can be increased when Metixene is combined with Etorphine.
Dextromoramide	The risk or severity of adverse effects can be increased when Metixene is combined with Dextromoramide.
Desomorphine	The risk or severity of adverse effects can be increased when Metixene is combined with Desomorphine.
Carfentanil	The risk or severity of adverse effects can be increased when Metixene is combined with Carfentanil.
Dihydrocodeine	The risk or severity of adverse effects can be increased when Metixene is combined with Dihydrocodeine.
Alphacetylmethadol	The risk or severity of adverse effects can be increased when Metixene is combined with Alphacetylmethadol.
Dihydromorphine	The risk or severity of adverse effects can be increased when Metixene is combined with Dihydromorphine.
Tapentadol	The risk or severity of urinary retention and constipation can be increased when Metixene is combined with Tapentadol.
Ketobemidone	The risk or severity of adverse effects can be increased when Metixene is combined with Ketobemidone.
DPDPE	The risk or severity of adverse effects can be increased when Metixene is combined with DPDPE.
Lofentanil	The risk or severity of adverse effects can be increased when Metixene is combined with Lofentanil.
Opium	The risk or severity of adverse effects can be increased when Metixene is combined with Opium.
Normethadone	The risk or severity of adverse effects can be increased when Metixene is combined with Normethadone.
Piritramide	The risk or severity of adverse effects can be increased when Metixene is combined with Piritramide.
Alphaprodine	The risk or severity of adverse effects can be increased when Metixene is combined with Alphaprodine.
Nicomorphine	The risk or severity of adverse effects can be increased when Metixene is combined with Nicomorphine.
Meptazinol	The risk or severity of adverse effects can be increased when Metixene is combined with Meptazinol.
Phenoperidine	The risk or severity of adverse effects can be increased when Metixene is combined with Phenoperidine.
Phenazocine	The risk or severity of adverse effects can be increased when Metixene is combined with Phenazocine.
Tilidine	The risk or severity of adverse effects can be increased when Metixene is combined with Tilidine.
Carfentanil, C-11	The risk or severity of adverse effects can be increased when Metixene is combined with Carfentanil, C-11.
Benzhydrocodone	The risk or severity of adverse effects can be increased when Metixene is combined with Benzhydrocodone.
Naloxegol	The risk or severity of adverse effects can be increased when Metixene is combined with Naloxegol.
Trospium	The risk or severity of adverse effects can be increased when Trospium is combined with Metixene.
Oxyphenonium	The risk or severity of adverse effects can be increased when Oxyphenonium is combined with Metixene.
Benzatropine	The risk or severity of adverse effects can be increased when Benzatropine is combined with Metixene.
Disopyramide	The risk or severity of adverse effects can be increased when Disopyramide is combined with Metixene.
Terfenadine	The risk or severity of adverse effects can be increased when Metixene is combined with Terfenadine.
Buclizine	The risk or severity of adverse effects can be increased when Metixene is combined with Buclizine.
Trihexyphenidyl	The risk or severity of adverse effects can be increased when Metixene is combined with Trihexyphenidyl.
Oxyphencyclimine	The risk or severity of adverse effects can be increased when Metixene is combined with Oxyphencyclimine.
Procyclidine	The risk or severity of adverse effects can be increased when Metixene is combined with Procyclidine.
Hyoscyamine	The risk or severity of adverse effects can be increased when Metixene is combined with Hyoscyamine.
Methscopolamine bromide	The risk or severity of adverse effects can be increased when Metixene is combined with Methscopolamine bromide.
Darifenacin	The risk or severity of adverse effects can be increased when Metixene is combined with Darifenacin.
Tridihexethyl	The risk or severity of adverse effects can be increased when Metixene is combined with Tridihexethyl.
Anisotropine methylbromide	The risk or severity of adverse effects can be increased when Metixene is combined with Anisotropine methylbromide.
Atropine	The risk or severity of adverse effects can be increased when Metixene is combined with Atropine.
Nicardipine	The risk or severity of adverse effects can be increased when Metixene is combined with Nicardipine.
Mecamylamine	The risk or severity of adverse effects can be increased when Metixene is combined with Mecamylamine.
Pirenzepine	The risk or severity of adverse effects can be increased when Metixene is combined with Pirenzepine.
Homatropine methylbromide	The risk or severity of adverse effects can be increased when Metixene is combined with Homatropine methylbromide.
Benzquinamide	The risk or severity of adverse effects can be increased when Metixene is combined with Benzquinamide.
Propantheline	The risk or severity of adverse effects can be increased when Metixene is combined with Propantheline.
Dicyclomine	The risk or severity of adverse effects can be increased when Metixene is combined with Dicyclomine.
Tropicamide	The risk or severity of adverse effects can be increased when Metixene is combined with Tropicamide.
Cocaine	The risk or severity of adverse effects can be increased when Metixene is combined with Cocaine.
Quinidine	The risk or severity of adverse effects can be increased when Metixene is combined with Quinidine.
Amantadine	The risk or severity of adverse effects can be increased when Metixene is combined with Amantadine.
Methantheline	The risk or severity of adverse effects can be increased when Metixene is combined with Methantheline.
Cycrimine	The risk or severity of adverse effects can be increased when Metixene is combined with Cycrimine.
Cyclopentolate	The risk or severity of adverse effects can be increased when Metixene is combined with Cyclopentolate.
Tolterodine	The risk or severity of adverse effects can be increased when Metixene is combined with Tolterodine.

Target Protein

Muscarinic acetylcholine receptor M1 CHRM1

Muscarinic acetylcholine receptor CHRM1

Referensi & Sumber

Link

Link

Contoh Produk & Brand

Produk: 0 • International brands: 4

International Brands

Cholinfall
Methixart
Tremaril
Tremarit

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.

Peringatan Keamanan

Deskripsi

Struktur Molekul 2D

Deskripsi metode visualisasi

1. Pendahuluan & Konsep

2. Sumber Data (Validasi)

3. Algoritma Visualisasi

4. Legenda Visual